Select Publications
Journal articles
2019, 'MiR-101 suppresses the development of MLL-rearranged acute myeloid leukemia', Haematologica, 104, pp. e296 - e299, http://dx.doi.org/10.3324/haematol.2018.209437
,2019, 'JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis', Leukemia, 33, pp. 1400 - 1410, http://dx.doi.org/10.1038/s41375-018-0354-z
,2019, 'A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction', Oncogene, 38, pp. 3824 - 3842, http://dx.doi.org/10.1038/s41388-018-0666-5
,2019, 'Macrophage-derived IL1B and TNFa regulate arginine metabolism in neuroblastoma', Cancer Research, 79, pp. 611 - 624, http://dx.doi.org/10.1158/0008-5472.CAN-18-2139
,2019, 'Transcriptome profiling of caspase-2 deficient EμMyc and Th-MYCN mouse tumors identifies distinct putative roles for caspase-2 in neuronal differentiation and immune signaling', Cell Death and Disease, 10, pp. 56, http://dx.doi.org/10.1038/s41419-018-1296-0
,2019, 'Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma', Science Translational Medicine, 11, http://dx.doi.org/10.1126/scitranslmed.aau1099
,2019, 'Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia', International Journal of Cancer, 146, pp. 1902 - 1916, http://dx.doi.org/10.1002/ijc.32582
,2019, 'Predictors of Success of Phase II Pediatric Oncology Clinical Trials', Oncologist, 24, pp. e765 - e774, http://dx.doi.org/10.1634/theoncologist.2017-0666
,2018, 'Clinical Importance of Myc Family Oncogene Aberrations in Epithelial Ovarian Cancer', JNCI: Cancer Spectrum, 2, pp. pky047, http://dx.doi.org/10.1093/jncics/pky047
,2018, 'Network modeling of microRNA-mRNA interactions in neuroblastoma tumorigenesis identifies miR-204 as a direct inhibitor of MYCN', Cancer Research, 78, pp. 3122 - 3134, http://dx.doi.org/10.1158/0008-5472.CAN-17-3034
,2018, 'Too many targets, not enough patients: Rethinking neuroblastoma clinical trials', Nature Reviews Cancer, 18, pp. 389 - 400, http://dx.doi.org/10.1038/s41568-018-0003-x
,2018, 'NANT 2012-01: Phase 1 study of DFMO and celecoxib with cyclophosphamide and topotecan for relapsed or refractory high-risk neuroblastoma.', JOURNAL OF CLINICAL ONCOLOGY, 36, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.10558
,2018, 'MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma', Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, 1861, pp. 235 - 245, http://dx.doi.org/10.1016/j.bbagrm.2018.01.007
,2018, 'A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children', British Journal of Haematology, 180, pp. 550 - 562, http://dx.doi.org/10.1111/bjh.15056
,2018, 'PO-028 Effective targeting of NAD+biosynthesis in patient-derived xenograft models of high-risk paediatric acute lymphoblastic leukaemia', ESMO Open, 3, pp. A238 - A238, http://dx.doi.org/10.1136/esmoopen-2018-eacr25.563
,2017, 'High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment', Haematologica, 102, pp. e490 - e493, http://dx.doi.org/10.3324/haematol.2016.162925
,2017, 'Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo', European Journal of Cancer, 83, pp. 132 - 141, http://dx.doi.org/10.1016/j.ejca.2017.06.024
,2017, 'A Myc activity signature predicts poor clinical outcomes in Myc-associated cancers', Cancer Research, 77, pp. 971 - 981, http://dx.doi.org/10.1158/0008-5472.CAN-15-2906
,2016, 'Polyamine antagonist therapies inhibit neuroblastoma initiation and progression', Clinical Cancer Research, 22, pp. 4391 - 4404, http://dx.doi.org/10.1158/1078-0432.CCR-15-2539
,2016, 'Gaq signaling is required for the maintenance of MLL-AF9-induced acute myeloid leukemia', Leukemia, 30, pp. 1745 - 1748, http://dx.doi.org/10.1038/leu.2016.24
,2016, 'MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin', Cancer Research, http://dx.doi.org/10.1158/0008-5472.CAN-15-0879
,2016, 'Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis', Molecular Oncology, 10, pp. 866 - 878, http://dx.doi.org/10.1016/j.molonc.2016.02.004
,2016, 'ABC transporters as mediators of drug resistance and contributors to cancer cell biology', Drug Resistance Updates, 26, pp. 1 - 9, http://dx.doi.org/10.1016/j.drup.2016.03.001
,2016, 'High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients', Cancer Letters, 374, pp. 315 - 323, http://dx.doi.org/10.1016/j.canlet.2016.02.021
,2016, 'CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements', Oncotarget, 7, pp. 46067 - 46087, http://dx.doi.org/10.18632/oncotarget.10022
,2016, 'Dextran-Catechin: An anticancer chemically-modified natural compound targeting copper that attenuates neuroblastoma growth', Oncotarget, 7, pp. 47479 - 47493, http://dx.doi.org/10.18632/oncotarget.10201
,2016, 'Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer', Oncotarget, 7, pp. 6353 - 6368, http://dx.doi.org/10.18632/oncotarget.7047
,2016, 'MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4', Oncotarget, 7, pp. 54937 - 54951, http://dx.doi.org/10.18632/oncotarget.10709
,2016, 'The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs', Oncotarget, 7, pp. 79217 - 79232, http://dx.doi.org/10.18632/oncotarget.12640
,2016, 'The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression', Oncotarget, 7, pp. 8663 - 8675, http://dx.doi.org/10.18632/oncotarget.6675
,2016, 'Predictors of success of phase 2 paediatric oncology clinical trials', European Journal of Cancer, 69, pp. S63 - S64, http://dx.doi.org/10.1016/s0959-8049(16)32778-2
,2016, 'Proffered Paper: Targeting PA2G4, a novel MYCN co-factor, for the treatment of neuroblastoma', European Journal of Cancer, 61, pp. S7 - S7, http://dx.doi.org/10.1016/s0959-8049(16)61016-x
,2015, 'Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma', Science Translational Medicine, 7, pp. 312ra176, http://dx.doi.org/10.1126/scitranslmed.aab1803
,2015, 'Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma', Molecular Oncology, 9, pp. 1484 - 1500, http://dx.doi.org/10.1016/j.molonc.2015.04.005
,2015, 'Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma', TRANSLATIONAL PEDIATRICS, 4, pp. 226 - 238, http://dx.doi.org/10.3978/j.issn.2224-4336.2015.04.06
,2015, 'Folate pathway gene polymorphisms and risk of childhood brain tumors: Results from an Australian case-control study', Cancer Epidemiology Biomarkers and Prevention, 24, pp. 931 - 937, http://dx.doi.org/10.1158/1055-9965.EPI-14-1248
,2015, 'Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia', British Journal of Haematology, 168, pp. 395 - 404, http://dx.doi.org/10.1111/bjh.13142
,2015, 'ABC Transporters and Neuroblastoma', , 125, pp. 139 - 170, http://dx.doi.org/10.1016/bs.acr.2014.10.005
,2015, 'Folate pathway gene polymorphisms, maternal folic acid use, and risk of childhood acute lymphoblastic leukemia', Cancer Epidemiology Biomarkers and Prevention, 24, pp. 48 - 56, http://dx.doi.org/10.1158/1055-9965.EPI-14-0680
,2015, 'MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma', Oncotarget, 6, pp. 15510 - 15523, http://dx.doi.org/10.18632/oncotarget.3732
,2014, 'GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis', Blood, 124, pp. 3284 - 3294, http://dx.doi.org/10.1182/blood-2013-10-532523
,2014, 'High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4)', Biochemical Pharmacology, 91, pp. 97 - 108, http://dx.doi.org/10.1016/j.bcp.2014.05.023
,2014, 'ABCA transporter gene expression and poor outcome in epithelial ovarian cancer', Journal of the National Cancer Institute, 106, pp. dju149, http://dx.doi.org/10.1093/jnci/dju149
,2014, 'Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer', Scientific Reports, 4, pp. 4669, http://dx.doi.org/10.1038/srep04669
,2014, 'USE OF NOVEL PATIENT-DERIVED XENOGRAFTS AND MOLECULAR SUBTYPING TO IMPROVE PRECISION MEDICINE IN HIGH-GRADE SEROUS OVARIAN CANCER', EUROPEAN JOURNAL OF CANCER, 50, pp. E9 - E9, http://dx.doi.org/10.1016/j.ejca.2014.03.042
,2014, 'The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1', Oncotarget, 5, pp. 1793 - 1804, http://dx.doi.org/10.18632/oncotarget.1785
,2014, 'Identification of plasma Complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach', Journal of Proteomics, 96, pp. 1 - 12, http://dx.doi.org/10.1016/j.jprot.2013.10.032
,2014, 'An unexpected role for caspase-2 in neuroblastoma', Cell Death and Disease, 5, pp. e1383 - e1383, http://dx.doi.org/10.1038/cddis.2014.342
,2014, 'Histone Deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1', Oncotarget, 5, pp. 4257 - 4268, http://dx.doi.org/10.18632/oncotarget.1991
,2014, 'Molecular profiling of childhood cancer: Biomarkers and novel therapies', BBA Clinical, 1, pp. 59 - 77, http://dx.doi.org/10.1016/j.bbacli.2014.06.003
,